&nbsp;

Oct 2023

Drug

niLOtinib

Other Name(s): Tasigna®

Quick Link(s):

Jul 2025

Drug

nab-PACLitaxel

Other Name(s): Abraxane®

Quick Link(s):

Dec 1969

Drug

octreotide

Other Name(s): Sandostatin® (multiple brands available) , Sandostatin® LAR™ (Novartis)

Quick Link(s):

Dec 1969

Drug

nelarabine

Other Name(s): Atriance®

Quick Link(s):

Dec 1969

Drug

oBINutuzumab

Other Name(s): Gazyva®

Quick Link(s):

Dec 1969

Drug

nivolumab

Other Name(s): Opdivo®

Quick Link(s):

Oct 2024

Drug

osimertinib

Other Name(s): Tagrisso®

Quick Link(s):

Dec 1969

Regimen

NPAC

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Nab-Paclitaxel - Metastatic Breast Cancer

Drugs Used:

nab-PACLitaxel

Quick Link(s):

Regimen Monograph

Nov 2023

Regimen

OCTR

Cancer Type:

Gastrointestinal,

Neuroendocrine (GI),

Lung,

Neuroendocrine (Lung)

Intent: Palliative

Funding:

ODB - General Benefit

octreotide

Drugs Used:

octreotide

Quick Link(s):

Regimen Monograph

Regimen

NILO

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

niLOtinib - Chronic phase Ph+ CML, with specific criteria

Exceptional Access Program

niLOtinib - Accelerated phase Ph+ CML with documented resistance or intolerance to imatinib therapy, with specific criteria

Drugs Used:

niLOtinib

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

NLTM

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

ODB - General Benefit

niLUTAmide

Drugs Used:

niLUTAmide